Treatment Landscape of Targeted Therapies in Oncology Challenges and Opportunities
Coordonnateurs : Maurya Pawan Kumar, Saini Vikas
Dr. Vikas Saini is working as an Assistant professor and Coordinator of Biomedical Sciences program under Department of Vocational Studies and Skill Development, Central University of Haryana, India. His area of interest is Cancer biology and drug discovery. He earned his Ph.D. in biomedical Sciences from Dr. B.R. Ambedkar Centre for Biomedical Research (ACBR), University of Delhi with an emphasis on identifying novel anticancer molecules. He has research experiences in the area of cheminformatics, drug synthesis, and cancer biology. He has more than 4 years of teaching experience and published several research articles and book chapters in reputed journals. He is currently working on testing novel compounds against cancer.
- Covers basic concepts and updated knowledge of the latest anticancer drugs
- Brings comprehensive understanding of the treatment of cancer in context of immunotherapy and targeted therapy
- Introduces the latest drugs and advancements in the treatment of cancer
- Includes detailed diagrams to give insight to the mechanisms of action
Date de parution : 08-2023
Ouvrage de 270 p.
19x23.4 cm
Thèmes de Treatment Landscape of Targeted Therapies in Oncology :
Mots-clés :
?Adjuvant therapy; BRCA gene; BRCA1 and BRCA2; Biomarkers; Breast cancer; Cancer; Cancer biology; Cancer therapy; Chemotherapy; Clinical implication; Colorectal cancer; Cyclin-dependent kinase; Drug resistance; EGFR; ER; Endometrial cancer; Gastric cancer; Gene therapy; Gliblastoma multiforme; HER-2; HER2; HNSCC; HPV; Head and neck squamous cell carcinoma; Her2-targeted therapy; Heterogeneity; Hormonal therapy; Immune checkpoint inhibitors; Immunotherapy; Lung cancer; MTOR; MTOR inhibitors; Malignant; Melanoma; Metastasis; Mitogen-activated protein kinase; Molecular markers; Molecular targeted therapy; Monoclonal antibodies; NTRK gene fusions; Nanocapsule; Nanocarriers; Nanoparticles; Nanotherapy; Obesity; Oncogenes; Oncology; PR; Pancreatic cancer; Parity; Radiation therapy; Radiotherapy; Raptor-mTOR; Resistance; Small molecule inhibitors; TKIs; TNBC; Targeted immunotherapy; Targeted therapy; Therapeutic approaches; Tumor suppressor genes; VEGF